We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to day +14 or to discharge. All patients were assessed for clinical status, mucositis, blood counts, oral intake and immune reconstitution. Parenteral nutrition was administered according to predefined guidelines. Forty patients were randomized; 21 into the glutamine and 19 into the placebo arm. Glutamine patients had less days with diarrhoea (3.3 ؎ 4.0 vs 4.3 ؎ 3.0, P = 0.03), but they had more severe oral mucositis (mean 4 ؎ 4.7 vs 1.4 ؎ 2.3 days of mucositis score Ͼ13, P = 0.04), spent more days on opioids (mean 3.5 ؎ 4.2 vs 1.2 ؎ 2.2 days, P = 0.03) and left hospital later than placebo patients (mean 13.5 ؎ 3.1 vs 11.7 ؎ 2.4 days after transplant, P = 0.06). There were more relapses (P = 0.02) and deaths (P = 0.05) in the glutamine group. The cost of supportive care (mean 2960 ؎ 1694 vs 1534 ؎ 513 Euro, P = 0.002) was also greater for glutamine patients, mainly due to the cost of glutamine dipeptide itself. The described mode and dosage of glutamine administration did not produce meaningful benefit in our autologous transplant patients and it was certainly not costeffective. 
receiving chemo/radiotherapy, [1] [2] [3] [4] including high-dose therapy (HDT) and stem cell transplant, [5] [6] [7] [8] with conflicting results. Furthermore, even in the positive studies the mechanism of possible clinical benefit was not clear. Data derived predominantly from animal studies have suggested that improved gut feeding results in faster mucosal recovery which could be responsible for the beneficial effect both in parenteral and enteral supplementation, 9, 10 while other authors ascribed this benefit to enteral glutamine formulas only. 8 Parenteral glutamine was shown to accelerate lymphocyte count recovery in one study, 6 which could result in faster immune reconstitution after anticancer treatment, especially after HDT. It should be emphasized that most of the published studies used non-standardized glutamineenriched formulas, prepared for the particular trial purposes only.
Dipeptiven (Fresenius-Kabi) is standardized, commercially available alanyl-glutamine dipeptide intended for parenteral use. 4, 9 The maximum daily dose recommended by the manufacturer is 30 g of Dipetiven, which corresponds to 20 g of parenteral glutamine. Our aim was to study the impact of this dose and mode of glutamine administration on clinical outcomes and costs of supportive care of autologous transplant patients. If any clinical benefit was found, the next question would be if the faster mucosal recovery or faster immune reconstitution were responsible for it.
Patients and methods

Funding
The funding of the study was solely from a grant from the Czech Ministry of Public Health (IGA 5502/3). All parenteral feeding solutions, including Dipeptiven, were purchased from the distributor at the usual commercial prices.
Patients
Forty consecutive, eligible patients were randomized. Inclusion criteria were a peripheral blood progenitor cell (PBPC) collection of at least 1 ϫ 10 6 /kg CD34 + cells (with or without supplemental bone marrow), adequate organ function, and any conditioning regimen other than paclitaxel with carboplatin used for ovarian cancer patients in the OVCAT trial 11 (these patients have a very short duration of cytopenia and insignificant mucositis). Patients receiving double-transplant programs were not a priori excluded, but they could enter this study only once. All participants signed informed consent approved by the Local Ethical Committee.
Study protocol
Patients were randomized to receive parenterally either 30 g of dipeptid alanyl-glutamine daily (Dipeptiven; FreseniusKabi) containing 20 g of glutamine (21 patients) or an isonitrogenous aminoacide solution (19 patients). Randomization was performed by a random-number method in the hospital pharmacy and was stratified according to patients diagnosis (myeloma patients vs others). This stratification was based on different lengths of conditioning regimen (1 day for myeloma patients vs 5-9 days in others) which resulted in apparently longer periods of neutropenia for the latter regimens. Except for the hospital pharmacist, all other personel involved in the trial were blinded, as were the patients. Glutamine dipeptide and non-glutamine amino acid solutions were further dissolved in 900 ml of normal saline and were indistinguishable from each other. Solutions were administered for 8 h daily from day +1 to day +14 after stem cell infusion, or to discharge from hospital.
Daily monitoring of full blood counts and absolute neutrophil count (ANC) were performed. Renal and liver function tests were assessed at least three times weekly and coagulation (PT, aPTT) at least twice weekly or according to clinical indication. Lymphocyte subpopulations (CD3, CD4, CD8, CD19, CD57) and immunoglobulin levels were assessed on admission, at days 0, +14, +28 and +42 after progenitor cell infusion.
Patients were nursed in single rooms and received antimicrobial prophylaxis consisting of ciprofloxacin 500 mg b.i.d., fluconazole 100 mg q.d. and valacyclovir 500 mg b.i.d. from day 0 or from the day when the ANC fell below 0.5 ϫ 10 9 /l. When the axillary temperature rose above 38°C, blood cultures for bacteria and fungi were taken and empirical broad-spectrum antibiotics were administered according to the institutional protocol which was not changed during the study period. Patients with proven infectious agents received antimicrobial treatment according to susceptibility profiles.
Febrile neutropenia was defined as axillary temperature >38°C with a neutrophil count <0.5 ϫ 10 9 /l. Bacteremia was defined as at least one positive blood culture. Pneumonia was defined as a new or enlarging infiltrate on chest X-ray together with axillary temperature >38°C and cough, dyspnoea or auscultation finding corresponding to the Xray appearances. Axillary temperature >38°C with neutrophil count >0.5 ϫ 10 9 /l, no clinical focus of infection and negative blood cultures were classified as other febrile episode.
Red cell concentrates were given to patients with haemoglobin levels less than 80 g/l or with clinical symptoms of anaemia. Platelet concentrates were given to patients with clinical bleeding, or prophylactically when the platelet count fell below 10 ϫ 10 9 /l. G-CSF (Neupogen; HoffmannLaRoche, Basel, Switzerland) was given subcutaneously at a dose of 5 g/kg from day +6, except for patients with multiple sclerosis, who received the same dose from day +3 after stem cell infusion. Patients with severe painful mucositis received intravenous opioid analgesics (tramadol or morphine) as needed.
Mucositis evaluation
Monitoring of oral mucositis consisted of quantitative evaluation of the Nebraska Oral Assessment Score for oral mucositis 12 by a trained transplant nurse. Eight different aspect of oral mucositis were evaluated quantitatively (grade one to three -see Table 1 ) and the individual item scores were summed to obtain an overall oral mucositis score. From the Nebraska Oral Assessment Score the following indexes were also recorded: MUCPEAK -the peak oral mucositis score reached in each individual patient, and MUC9, MUC10, MUC11, MUC12, MUC13, MUC14 -the number of days with mucositis of at least the particular score. Symptoms of mucositis of other parts of the gastrointestinal tract were evaluated qualitatively on a yes/no basis. Diarrhoea was defined as more than three loose stools daily. Total days of diarrhoea, nausea and vomiting were counted for each patient.
For evaluation of small bowel mucositis, the 5 g Dxylose absorption test was performed, as described elsewhere. 13, 14 Patients received a 5 g oral dose of D-xylose in the morning while fasting. Blood samples were obtained before and 1 h after the oral dose of D-xylose. The serum concentrations of D-xylose were determined spectrophotometrically. These tests were performed on admission, on day 0 and on days +7, +14 and +28 after stem cell infusion. 
Measurements of basal metabolism, oral intake and parenteral nutrition
Albumin, prealbumin, cholinesterase and C-reactive protein levels were taken on admission, at discharge, and on days +14, +28 and +42 after progenitor cell infusion. Measurements of lean body mass (LBM), total body water, extra and intracellular water (TBW, ECV, ICV) and other parameters were assessed by bioelectric impedancy with a BIA 2000-M device (Data Input, Frankfurt, Germany) at the same time points, and on one further occasion on day +100. Oral intake was assessed daily by a qualified, blinded dietitian and counted as kilocalories (kcal) with the use of 'Progana' and 'Diety' software (Ostrasoft; Ostrava, Czech Republic). Adequacy of oral intake was evaluated on the basis of resting energy expenditure (REE) estimated by the Harris-Benedict formula. Parenteral nutrition based on Nutriflex special (B Braun Medical, Melsungen, Germany) and Intralipid (Fresenius-Kabi) at a dose of 26.5 kcal/kg and 1 g of protein/kg was given to patients who did not have adequate oral intake for 5 days (assessed as less than 50% of 1.25ϫ REE estimate). Prior to the administration of TPN, patients received dietary counselling from a specialized nurse to optimize the oral feeding schedule. Parenteral nutrition was witheld after 2 consecutive days of oral intake at least 50% of 1.25ϫ REE estimate. Patients with a body mass index (BMI) >27 kg/m 2 were given 34 kcal/kg of lean body mass (LBM -see below) and 1.3 g of protein/kg LBM.
Economic calculations
Prices of antibiotics, parenteral nutrition, growth factors and blood products were calculated from the distributor on 1 January 2000. The costs of these four components of supportive care were calculated separately and then added together to get the total supportive care cost. For patients receiving glutamine supplementation, the cost of Dipeptiven was added to the total supportive care cost, but not to the parenteral nutrition cost. Other costs were not included in the economic analysis, because these were included in standard hospital-day payments, which were the same for all patients on the transplant unit. For patients transferred to ICU, the costs of ICU care were not calculated. Prices in Czech crowns were converted to Euros based on the approximate exchange rate 1 Euro = 30 Czk.
Statistical analysis
Primary endpoints were clinical outcomes in terms of infection rates (peritransplant and post transplant), need for antibiotics, opioid analgesics, parenteral nutrition, length of hospitalization after stem cell infusion, and the cost of supportive care. Secondary endpoints were severity of mucositis (Nebraska Oral Assessment Score, nausea, vomiting and diarrhoea); immune reconstitution in terms of regeneration of lymphocyte subpopulations and immunoglobulin levels, and the cost of supportive care components (growth factors, antibiotics, TPN and blood products). Overall and relapse-free survival were also considered secondary endpoints, because no significant differences were expected.
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No formal calculation of statistical power of the study was performed because at the the time of study design there were no studies of glutamine supplementation in autologous transplant population published. Thus, our study size estimate was based on Ziegler et al's study, 5 which showed a statistically significant reduction in post-transplant hospital stay (36 vs 29 days, P = 0.017) in 45 allogeneic transplant patients and in clinical infections (12% vs 43%) in the glutamine vs placebo group (P = 0.04). Similarly, Houdijk et al 11 showed very similar reductions in clinical infections (pneumonia, 17% vs 45%, P < 0.02 and bacteraemia, 7% vs 42%, P < 0.005) for the enteral glutamine vs placebo group in a total of 60 multiple trauma patients, and Schloerb and Amare in their pilot study 7 found a significant difference in hospital stay in only 29 randomized patients. Therefore, it was expected that a study with 40 randomized patients should show at least a trend towards better results in the glutamine group, if there were any.
Four multiple sclerosis patients who received T celldepleted grafts (n = 2) or ATG after progenitor cell infusion (n = 2), and had different growth factor schedules, were not included in the analyses of engraftment, lymphocyte recovery and growth factor utilization. Immunoglobulin concentrations were evaluated in the non-myeloma patients only, because in myeloma these values are dependent primarily on disease activity. In three patients transferred to ICU after transplant (two in the glutamine and one in the placebo group), only the costs of supportive care before transfer to ICU were counted for logistic reasons.
Comparison of numerical variables between the two groups was done with the Student's t-test and Mann-Whitney U test. Means and Student's P values are used to present the data in this article, unless stated otherwise. Categorical data were evaluated using Mantel-Haenszel tests. To analyse repeated measurements (day Ϫ10 to day 20) we used ANOVA or logistic regression with factors, day and person. Survival times were measured according to the Kaplan-Meier methods and survival differences were analysed with the logrank test. All analyses were done on an intention-to-treat basis and all statistical significances were counted as two-tailed. Statistical calculations were performed on the SPSS v10. software.
Results
Patient characteristics
The main characteristics of the patient cohort are shown in Table 2 . Patients with myeloma (n = 11) were older (mean 53 vs 42 years, P = 0.005) and received less CD34 + cells than other patients (mean 2.86 vs 4.73 ϫ 10 6 /kg, P = 0.003). In 29 out of 40 patients (72%) the transplant was performed as a part of the first-line treatment with no differences between glutamine and placebo groups. Ten patients were included in tandem transplant protocols (eight myeloma, one lymphoma and one breast cancer patient), five were randomized to placebo and five to glutamine. Only two of the myeloma patients (one glutamine, one placebo) were randomized during second high-dose procedures. One additional AML patient, randomized into the Table 2 Characteristics of patients on admission 
Clinical results
Clinical and laboratory results are shown in Table 3 . 1.2 Ϯ 2.2 days, P = 0.04). The oral intake and number of days on TPN were comparable in both groups, as oral intake depended on severity of mucositis only, not on treatment assignment (data not shown).
There were no differences in the number of febrile days or clinical infections between glutamine and placebo patients. Patients receiving glutamine had a mean of 2.5 Ϯ 2.9 febrile days vs 1.3 Ϯ 1.4 febrile days in placebo patients (P = 0.09). Eight glutamine and six placebo patients had positive blood cultures and three glutamine and one placebo patient had clinically proven infections. There was no difference in number of days on antibiotics, but glutamine patients spent more days on vancomycin than placebo patients (3.6 Ϯ 5.3 vs 0.8 Ϯ 1.8 days, P = 0.03). There were no differences in neutrophil or platelet recovery, or in the use of platelet or red cell concentrates. Glutamine patients tended to stay longer in hospital after stem cell infusion (13.5 Ϯ 3.1 vs 11.7 Ϯ 2.4 days, P = 0.06).
Three patients were transferred to the intensive care unit (ICU) in the peritransplant period (two glutamine, one placebo) and two of them survived; the non-survivor (a 55-year-old woman with NHL) died from interstitial pneumonia and was the only non-relapse death in the cohort. No renal, hepatic or other toxicity attributable to glutamine was identified.
After a median follow-up of 24 months, 13 patients have relapsed (three placebo, 10 glutamine), and seven patients have died (one placebo, six glutamine). These results were statistically significant (P = 0.05 for overall and 0.02 for relapse-free survival, log-rank test, Figures 1 and 2) .
Laboratory results
There were no differences among the glutamine and placebo groups in terms of changes of body weight, lean body mass, total body water and its subcomponents, albumin, prealbumin or CRP levels. Also, lymphocyte and immunoglobulin reconstitution did not differ between the glutamine and placebo subgroups. The largest numerical differences are shown in Table 3 ; however, none of them reached statistical significance.
The D-xylose absorption test showed the small bowel malabsorption being most prominent on day +7 after stem cell infusion with return to pretreatment values on day +28. There was no difference in the results of this test between placebo and glutamine patients ( Table 4) .
Costs of supportive care
The costs of supportive care in patients receiving glutamine dipeptide were almost twice as high as in patients receiving placebo (mean 2960 Ϯ 1694 vs 1534 Ϯ 662 Euro, P = 0.002). The main difference was the cost of glutamine dipeptide itself (mean 780 Ϯ 162 Euro per patient), but the higher cost of antibiotics in the glutamine group (mean 628 Ϯ 773 vs 223 Ϯ 242 Euro for placebo, P = 0.03) also contributed. There were no significant differences between the cost of TPN, blood products or growth factors.
Additional calculations
As patients with AML tend to have more treatment complications, 12 multiple sclerosis is not a standard indication for BMT, and double transplants may not be considered as standard procedures, results were recalculated with a posteriori exclusion of these subgroups. All the trends remained the same, although some of the differences lost statistical significance. Also, the use of medians instead of means and Mann-Whitney U test instead of Student's ttest confirmed the consistency of the results (Table 5) .
Discussion
Any form of supportive care which is cost-effective should produce better clinical results than placebo, and should achieve these results without unacceptably high resource utilization. To our knowledge, this randomized, double-blind study is the first to evaluate the commercially available parenteral glutamine formula in autologous transplant patients which also includes economic analysis. This study shows that glutamine supplementation produced modest benefit in terms of large bowel mucositis, measured as number of days with diarrhoea. However, it did not have any effect either on oral mucositis, scored according to the Nebraska Oral Assessment system, or on small bowel mucositis, as evident from the D-xylose absorption test. Furthermore, patients on glutamine spent more days on parenteral opioids and had slightly longer hospital stays after stem cell infusion. Interestingly, there was also an excess of relapses and deaths in the glutamine group. The cost of antibiotics and of total supportive care was significantly higher in glutamine-supplemented patients -the price of alanyl-glutamine supplementation itself adding substantially to the increased resource utilization. There are several possible explanations for failure of our study to show a benefit for glutamine in autologous transplant patients. The inadequate power of our study could be one of these. However, most of the published studies recruited similar numbers of patients, with some of them showing results significantly in favor of glutamine supplementation. 2, 5, 7 Contrary to these findings, our study showed a worse outcome for some of the clinical parameters, and higher cost of supportive care for glutamine-supplemented patients. In this study, it is improbable that higher recruitment would have led to the opposite results. 16 The heterogeneity of our patient population could be another explanation. Similar heterogeneity, however, can be found in most of the previously published papers. [2] [3] [4] 7, 8, 17, 18 This heterogeneity probably results from the fact that even in large institutions it is extremely difficult to gather an adequately-sized homogenous cohort of patients for a prospective study of supportive care, especially when the target group most likely to benefit from experimental treatment is not well defined. However, with the possible exception of the two AML patients, we found Ϯ means a trend towards positive result which did not reach statistical significance.
Bone Marrow Transplantation no evidence that our patients randomized into the glutamine arm were sicker or in more advanced disease stages than the placebo patients. Furthermore, our results were consistent using different statistical methods and after a posteriori exclusion of this and some other patient subgroups (Table 5) . It could be postulated that statistical factors may be relevant in the apparent discrepancy between the results of our study and some of the positive ones. If moderate treatment effects are to be reliably detected in prospective trials, both systematic errors (biases) and random errors have to be excluded. 19 Our study was constructed in 1998 and four of six studies published up to 1998 gave positive results. However, after 1998, three studies with negative results (including the current one) have been published. In three studies, [20] [21] [22] which were interpreted as positive, there was, in fact, no clinical benefit, and in the other two the possible clinical benefit was not statistically significant. Only one other study, 23 assessing the effect of glutamine on paclitaxel-induced neurotoxicity reported unequivocally positive clinical results (Table 6 ). Thus, the possibility of publication bias in the first period cannot be excluded. The only way of eliminating publication bias is to publish negative studies along with positive ones.
Random errors are those which are related to chance rather than treatment or outcome. It is well-known that in small studies 'false positive' as well as 'false negative' results can be achieved, sometimes with high statistical significance. However, if studies of much larger size are conducted, results can differ. 24, 25 Thus, even in the absence of bias in our study, we cannot exclude that, for example, our results of survival analysis could be due to random error. Nevertheless, this also implies that any benefit, which may eventually be found in a much larger study, is likely to be modest.
The only way to prove the role of glutamine in cancer treatment would be to arrange a multicentre study which would recruit patients at particular risk of treatment-related complications or death. Data from studies presented in Table 6 could be used to some extent to define the target patient population and preferential mode of glutamine administration. In both oral and parenteral supplementation studies, positive results were achieved. However, in the positive studies of oral supplementation, glutamine was given as a thick suspension instead of liquid. It is possible that this mode of administration may be more efficaous, irrespective of the dose of glutamine. 2, 3, 8, 26, 27 Daily dose may be more important in parenteral then enteral glutamine, as in the positive studies approximately twice the dose of glutamine was given compared to our study and other negative studies. 5, 7, 17 However, the dose of alanyl-glutamine dipeptide used in our study was based on recommendations distributed by the manufacturer at the time the study was designed.
Irrespective of the mode of administration, allogeneic transplant patients seemed to benefit most from glutamine supplementation, especially when total body irradiation was used. 6 For oral mucosa protection, it may be more advantageous to start glutamine together with the conditioning regimen rather than after conditioning 2, 8, 26 and to add small doses of oral glutamine suspension to the parenteral supplementation. A well-designed, multicentre study in a homogenous group of patients -in this case, probably patients with acute and chronic leukaemia receiving allogeneic transplantation 6 -could help to establish the role of glutamine in stem cell transplant procedures.
At present, the available data are insufficient to support the routine use of glutamine supplementation in transplantation medicine -beneficial results are at most modest, and not cost-effective.
